Last reviewed · How we verify
Aspirin with P2Y12 receptor inhibitor
Aspirin with P2Y12 receptor inhibitor is a Small molecule drug developed by Dong-A University. It is currently FDA-approved. Also known as: Control group.
At a glance
| Generic name | Aspirin with P2Y12 receptor inhibitor |
|---|---|
| Also known as | Control group |
| Sponsor | Dong-A University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM) (NA)
- Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction (PHASE4)
- Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis (PHASE3)
- Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial). (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin with P2Y12 receptor inhibitor CI brief — competitive landscape report
- Aspirin with P2Y12 receptor inhibitor updates RSS · CI watch RSS
- Dong-A University portfolio CI
Frequently asked questions about Aspirin with P2Y12 receptor inhibitor
What is Aspirin with P2Y12 receptor inhibitor?
Aspirin with P2Y12 receptor inhibitor is a Small molecule drug developed by Dong-A University.
Who makes Aspirin with P2Y12 receptor inhibitor?
Aspirin with P2Y12 receptor inhibitor is developed and marketed by Dong-A University (see full Dong-A University pipeline at /company/dong-a-university).
Is Aspirin with P2Y12 receptor inhibitor also known as anything else?
Aspirin with P2Y12 receptor inhibitor is also known as Control group.
What development phase is Aspirin with P2Y12 receptor inhibitor in?
Aspirin with P2Y12 receptor inhibitor is FDA-approved (marketed).
Related
- Manufacturer: Dong-A University — full pipeline
- Also known as: Control group
- Compare: Aspirin with P2Y12 receptor inhibitor vs similar drugs
- Pricing: Aspirin with P2Y12 receptor inhibitor cost, discount & access